EPHA2 and prostate cancer: Using a TMA of archival primary prostate cancer tissue linked to long-term clinical outcome data we have shown that EphA2 and pEphA2S897 are associated with substantially worse long-term survival in PTEN-deficient prostate cancer and that the migrational stimulatory effect is most pronounced at the tumour margin.